Biohaven: regulation fd disclosure

Form 8-K filed Oct 22, 2026 · items 7.01

What the filing says

On October 22, 2026, Biohaven Ltd. (the Company) provided an update on the spinocerebeller ataxia (SCA) program. The FDA has informed Biohaven that the company’s new drug application resubmission for Vyglxia (troriluzole) in SCA has been accepted for review.

Read the filing on SEC EDGAR →

Other recent fda decisions

Biovie Nov 6, 2026
Acrivon Therapeutics Nov 6, 2026
Entera Bio Nov 6, 2026
Precision Biosciences Nov 5, 2026
Sintx Technologies Nov 5, 2026
Microbot Medical Nov 5, 2026
Bioxytran Nov 5, 2026
Palvella Therapeutics Nov 5, 2026
ANI Pharmaceuticals Nov 5, 2026
Teleflex Nov 5, 2026

Read automatically from SEC EDGAR (13F, Form 4, Form 144, Schedule 13D/G, 8-K, XBRL), House and Senate disclosures, FINRA and exchange data; errors are possible. Not investment advice.